Emergent BioSolutions (EBS) Tops Q3 EPS by 28c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street rallies after Democrats win Congress; data center stocks slide
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts EBS Hot Sheet
Price: $6.32 +1.12%
Financial Fact:
Contracts and grants: 31.5M
Today's EPS Names:
ATS, SICP, FTCO, More
Financial Fact:
Contracts and grants: 31.5M
Today's EPS Names:
ATS, SICP, FTCO, More
Join SI Premium – FREE
Emergent BioSolutions (NYSE: EBS) reported Q3 EPS of $0.83, $0.28 better than the analyst estimate of $0.55. Revenue for the quarter came in at $164.9 million versus the consensus estimate of $151.42 million.
Emergent BioSolutions sees FY2015 revenue of $510-540 million.
For earnings history and earnings-related data on Emergent BioSolutions (EBS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Southwest Gas (SWX) Tops Q3 EPS by 2c; Offers Guidance
- Reservoir Media, Inc. (RSVR) Tops Q2 EPS by 2c; offers guidance
- XPEL, Inc. (XPEL) Tops Q3 EPS by 4c, Misses on Revenue; Offers Q4 Revenue Guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
